EUVIMEDEUVIMED entdecken
Open Access

Relative Efficacies of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Treatment of Recurrent Non-Small Cell Lung Cancer after Surgery

Nozomu Motono, Takaki Mizoguchi, Masahito Ishikawa, Shun Iwai, Yoshihito Iijima, Hidetaka Uramoto

Oncology · 2024

DOI: 10.1159/000534814 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Nozomu Motono und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Kanazawa Medical University, Uchinada, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, ErbB Receptors, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The relative efficacies of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) for the treatment of recurrent non-small cell lung cancer (NSCLC) after surgery remain unclear.

Methods

Among 801 patients with NSCLC who underwent pulmonary resection at Kanazawa Medical University between 2017 and 2021, sixty-four patients had recurrence. We retrospectively compared the efficacies of EGFR-TKIs and ICIs in these patients with recurrent NSCLC who underwent pulmonary resection.

Results

The 3-year overall survival rates after recurrence were 79.3% in patients who received EGFR-TKIs, 69.5% in patients who received ICIs, and 43.7% in patients who received cytotoxic agents. There was no significant difference in overall survival between patients treated with EGFR-TKIs and ICIs (p = 0.14) or between patients treated with ICIs and cytotoxic agents (p = 0.23), but overall survival was significantly higher in patients treated with EGFR-TKIs compared with cytotoxic agents (p < 0.01). The probabilities of a 2-year response were 88.5%, 61.6%, and 25.9% in patients treated with EGFR-TKIs, ICIs, and cytotoxic agents, respectively. There was no significant difference in response periods between patients treated with EGFR-TKIs and ICIs (p = 0.18), but the response period was significantly better in patients treated with EGFR-TKIs (p < 0.01) or ICIs (p = 0.03) compared with cytotoxic agents. Percent-predicted vital capacity (p = 0.03) and epidermal growth factor receptor gene mutation (p < 0.01) were significant factors affecting the overall response to chemotherapy in multivariate analysis.

Conclusion

EGFR-TKIs and ICIs are effective for treating recurrent NSCLC after surgery. Although adjuvant chemotherapy for completely resected pathological stage II to IIIA NSCLC, atezolizumab or osimertinib, has also been recently approved as adjuvant chemotherapy, there is a risk that patients who relapse after adjuvant chemotherapy will have less choice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsErbB ReceptorsImmune Checkpoint InhibitorsProtein Kinase InhibitorsNeoplasm Recurrence, LocalHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAged, 80 and overAdultTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

ChemotherapyEpidermal growth factor receptor-tyrosine kinase inhibitorImmune checkpoint inhibitorNon-small cell lung cancerPostoperative recurrence

Substanzen

ErbB ReceptorsImmune Checkpoint InhibitorsProtein Kinase InhibitorsEGFR protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Kanazawa Medical University, Uchinada, Japan.

Zitieren

APA

Motono, N., Mizoguchi, T., Ishikawa, M., Iwai, S., Iijima, Y., & Uramoto, H. (2024). Relative Efficacies of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Treatment of Recurrent Non-Small Cell Lung Cancer after Surgery. Oncology. https://doi.org/10.1159/000534814

Vancouver

Motono N, Mizoguchi T, Ishikawa M, Iwai S, Iijima Y, Uramoto H. Relative Efficacies of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Treatment of Recurrent Non-Small Cell Lung Cancer after Surgery. Oncology. 2024. doi:10.1159/000534814

BibTeX
@article{Motono2024,
  author = {Motono, Nozomu and Mizoguchi, Takaki and Ishikawa, Masahito and Iwai, Shun and Iijima, Yoshihito and Uramoto, Hidetaka},
  title = {Relative Efficacies of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Treatment of Recurrent Non-Small Cell Lung Cancer after Surgery},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000534814}
}
Kostenlos starten →